eFFECTOR Therapeutics (EFTRW) News Today → What’s Really Next for America… (From Porter & Company) (Ad) Free EFTRW Stock Alerts $0.02 0.00 (0.00%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 4, 2024 | marketbeat.comTrading was temporarily halted for "EFTRW" at 08:04 AM with a stated reason of "News pending."February 5, 2024 | finance.yahoo.comeFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 4, 2024 | thestreet.comeFFECTOR Therapeutics Inc. WarrantJanuary 12, 2024 | marketbeat.comTrading was temporarily halted for "EFTRW" at 07:01 PM with a stated reason of "News pending."January 9, 2024 | finance.yahoo.comeFFECTOR Therapeutics Announces Reverse Stock SplitJanuary 9, 2024 | finance.yahoo.comeFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024December 8, 2023 | seekingalpha.comeFFECTOR updates Phase 1/2 data for breast cancer therapyDecember 2, 2023 | markets.businessinsider.comBuy Rating for eFFECTOR Therapeutics Backed by FDA Fast Track and Promising Clinical DataNovember 30, 2023 | msn.comeFFECTOR Therapeutics 10% owner SR One Capital Management discloses sale of 609,163 sharesNovember 28, 2023 | finance.yahoo.comeFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast CancerNovember 27, 2023 | finanznachrichten.deeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 24, 2023 | benzinga.comeFFECTOR Therapeutics Stock (NASDAQ:EFTR), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comeFFECTOR Therapeutics Stock (NASDAQ:EFTR) Dividends: History, Yield and DatesNovember 19, 2023 | thestreet.comeFFECTOR Therapeutics Inc.November 15, 2023 | finance.yahoo.comeFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual MeetingNovember 13, 2023 | finance.yahoo.comeFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | finance.yahoo.comeFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare ConferenceOctober 24, 2023 | finance.yahoo.comeFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTRW and its competitors with MarketBeat's FREE daily newsletter. Email Address America could fall from this event (Ad)America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash. Click here to see how you can protect yourself today. EFTRW Media Mentions By Week EFTRW Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EFTRW News Sentiment▼0.440.57▲Average Medical News Sentiment EFTRW News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EFTRW Articles This Week▼20▲EFTRW Articles Average Week Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTRW and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DRTSW News ARTLW News BCTXW News FBIOP News GOVXW News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EFTRW) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressNo experience to confident trader, meet my student…Wealth Builders InstituteThe only AI company you should be looking atBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
